Introduction {#s1}
============

Lung cancer incidence, particularly adenocarcinoma,[@R1] is increasing globally and the disease remains the most commonly diagnosed cancer. The majority of patients (85%) are diagnosed with non-small cell lung cancer (NSCLC)[@R2] and, within this population, adenocarcinoma and squamous cell carcinoma are the two major histological subtypes, accounting for ∼45% and 25% of cases, respectively, with large variations according to geographical location.[@R3] [@R4] Up to 45% of patients with advanced NSCLC experience disease progression during first-line chemotherapy,[@R5] and all patients with initial disease control will eventually experience progression and require subsequent therapy.

Until 2014, the available agents for the second-line treatment of advanced NSCLC without driver mutations included docetaxel (Taxotere; Sanofi-Aventis, Bridgewater, USA), pemetrexed (Alimta; Eli Lilly, Indianapolis, USA) (non-squamous patients only) and erlotinib (Tarceva, Genentech/OSI Pharmaceuticals/Roche).[@R8] [@R9] In this review, we will examine the role of recently approved novel therapies in the management of patients with NSCLC, with a particular focus on antiangiogenic agents and immune checkpoint inhibitors following first-line chemotherapy.

Tumour angiogenesis: a treatment target {#s2}
=======================================

Angiogenesis is widely accepted as a fundamental process for the growth of primary tumours and their subsequent metastases,[@R10] involving multiple receptors and their associated pathways ([figure 1](#ESMOOPEN2016000118F1){ref-type="fig"}).

![Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Reprinted by permission from Macmillan Publishers: Llovet *et al*[@R53] copyright 2015. FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.](esmoopen-2016-000118f01){#ESMOOPEN2016000118F1}

Vascular endothelial growth factor (VEGF) has a prominent role in angiogenesis, mediating its effects via endothelial cells; consequently, the VEGF/VEGF receptor (VEGFR) pathway has been a very attractive therapeutic target.[@R10] Proangiogenic pathways have substantial redundancy, allowing tumours to bypass the inhibition of a single pathway and to adapt to the presence of antiangiogenic agents.[@R11] Acquired resistance involves interaction between cells and the tumour microenvironment, and uses various different proangiogenic pathways (including fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and other signalling pathways) to recruit vasculature.[@R11] [@R12] The tumour microenvironment---which includes both the malignant transformed cells, and also stromal, immune and endothelial cells---also plays a role in tumour progression.[@R13] It is postulated that non-malignant cells, including immune cells that infiltrate a tumour, acquire tumour-promoting functions, including encouraging the creation of new blood vessels and facilitating rapid expansion and progression towards malignancy.

The two main types of antiangiogenic agents that have been investigated in NSCLC are monoclonal antibodies and small-molecule tyrosine kinase inhibitors (TKIs), both of which target specific angiogenic receptors and pathways ([table 1](#ESMOOPEN2016000118TB1){ref-type="table"}).

###### 

Targeted agents influencing angiogenesis evaluated in NSCLC

  Agent          Description                    Target
  -------------- ------------------------------ ------------------------------------------------
  Bevacizumab    MAb                            VEGF-A
  Ramucirumab    MAb                            VEGFR-2
  Anlotinib      TKI                            VEGFR-2--3
  Apatinib       TKI                            VEGFR-2
  Axitinib       TKI                            VEGFR-1--3, PDGFR, c-kit
  Cediranib      TKI                            VEGF-1--3
  Fruquintinib   TKI                            VEGFR-1--3
  Lenvatinib     TKI                            VEGFR-1--3, PDGFR-α, FGFR-1--4, RET and c-kit
  Motesanib      TKI                            VEGFR-1--3, PDGFR, kit, RET
  Nintedanib     TKI                            VEGFR-1--3, FGFR-1--3, PDGFR-α/β
  Pazopanib      TKI                            VEGFR, PDGFR and c-kit
  Sorafenib      TKI                            VEGFR-1--3, RET, PDGFR, Flt-3, c-kit
  Sunitinib      TKI                            VEGFR-1/2, PDGFR-α/β, Flt-3 and c-kit
  Vandetanib     TKI                            VEGFR, EGFR, RET
  Aflibercept    Decoy receptor                 All VEGF-A isoforms, VEGF-B, PIGF
  Endostar       Recombinant human endostatin   VEGF-induced phosphorylation of VEGFR-2, FGF-2

EGFR, epidermal growth factor receptor; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; MAb, monoclonal antibody; NSCLC, non-small cell lung cancer; PDGFR, platelet-derived growth factor receptor; PlGF, placental growth factor; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

Bevacizumab (Avastin; Genentech/Roche, Basel, Switzerland), a humanised monoclonal antibody that binds to VEGF-A, provided proof-of-principle for antiangiogenic therapy in NSCLC in combination with first-line platinum-based chemotherapy and is approved in patients with advanced non-squamous NSCLC.[@R14] Subsequent extensive investigation of other antiangiogenic agents in advanced NSCLC did not result in regulatory approvals in the first-line or maintenance setting.[@R11] However, promising results were reported in previously treated patients with NSCLC.

Antiangiogenic agents {#s3}
=====================

Over the past decade, numerous clinical trials involving novel agents in patients with NSCLC who progressed on first-line therapy reported modest improvements in progression-free survival (PFS) but no significant improvements in overall survival (OS). These include vandetanib (ZODIAC, ZEAL and ZEST trials),[@R15] aflibercept (VITAL),[@R18] bevacizumab (BeTa)[@R19] and sunitinib (SUN1087)[@R20] [@R21] as monotherapy, or in combination with chemotherapy (docetaxel or pemetrexed) or erlotinib.

In 2014, two antiangiogenic agents were approved for patients with advanced NSCLC after first-line chemotherapy. The results of the LUME-Lung 1 trial (NCT00805194, study 1199.13) first led to European Union (EU) approval of nintedanib (Vargatef; Boehringer Ingelheim, Ingelheim, Germany), in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy.[@R22] Subsequently, results of the REVEL trial (NCT01168973, study 13852) led to the US and EU approvals of ramucirumab (Cyramza; Eli Lilly, Indianapolis, USA) in combination with docetaxel for patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy.[@R22] [@R23]

Nintedanib {#s3a}
----------

Nintedanib is an oral, triple angiokinase inhibitor that inhibits VEGFR-1--3, FGF receptors 1--3 and PDGF receptor-α and PDGF receptor-β.[@R24] Nintedanib also inhibits FLT3 and the Src kinase family.

Two phase III trials assessed the efficacy and safety of nintedanib.[@R25] [@R26] Both studies were similar in design: multinational, randomised, double-blind, placebo-controlled trials conducted in Eastern Cooperative Oncology Group performance score (ECOG PS) 0--1 patients with histologically or cytologically confirmed stage IIIB/IV or recurrent NSCLC after one previous platinum-based chemotherapy.[@R25] [@R26]

In LUME-Lung 1, 1314 patients were randomised to receive nintedanib (200 mg two times a day, n=655) or placebo (n=659) on days 2--21 in combination with docetaxel (75 mg/m^2^) on day 1, every 3 weeks. The two major histologies were adenocarcinoma (n=658) and squamous cell carcinoma (n=555). The study met its primary end point of PFS by independent central review, with nintedanib plus docetaxel showing significant improvement in median PFS versus placebo plus docetaxel (3.4 vs 2.7 months, HR 0.79, p=0.002) independent of histology.[@R25] The key secondary end point, OS, was tested in a prespecified stepwise order, maintaining adequate power: first, in patients with adenocarcinoma histology who progressed within 9 months after the start of first-line therapy; then in all adenocarcinoma patients; and then in the overall population. A significant increase in median OS (10.9 vs 7.9 months, HR 0.75, 95% CI 0.60 to 0.92, p=0.007) was observed in the nintedanib arm versus the placebo arm in patients with adenocarcinoma histology who progressed within 9 months after the start of first-line therapy ([figure 2](#ESMOOPEN2016000118F2){ref-type="fig"}A). In the adenocarcinoma population, median OS was longer than 1 year in the nintedanib arm and significantly longer than in the placebo arm (12.6 vs 10.3 months, HR 0.83, 95% CI 0.70 to 0.99, p=0.036) ([figure 2](#ESMOOPEN2016000118F2){ref-type="fig"}B). In the overall population, the 1-month increase in median OS in the nintedanib arm was not statistically significant (HR 0.94, 95% CI 0.83 to 1.05, p=0.272) ([figure 2](#ESMOOPEN2016000118F2){ref-type="fig"}C). In an exploratory analysis of chemorefractory adenocarcinoma patients with disease progression as best response to first-line therapy, treatment with nintedanib also significantly increased survival (median OS 9.8 vs 6.3 months, HR 0.62, 95% CI 0.41 to 0.94 p=0.025). Further exploratory analysis reported decreased tumour burden and decelerated tumour growth over time in the nintedanib arm compared with the placebo arm in adenocarcinoma patients, including patients with the poorest prognosis.[@R27]

![Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of \<9 months (A), all patients with adenocarcinoma (B) and the total population (C) from LUME-Lung 1. Patients without documented death were censored at the date of last contact when the patient was known to be alive. Adapted from Reck *et al*.[@R25] Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. 143--155, Copyright (2014), with permission from Elsevier.](esmoopen-2016-000118f02){#ESMOOPEN2016000118F2}

In the overall population, there were higher incidences in the nintedanib arm than in the placebo arm of diarrhoea (all grades: 42% vs 22%; grade ≥3: 7% vs 3%), liver-enzyme elevations (aspartate aminotransferase, all grades: 23% vs 7%; grade ≥3: 3% vs 1%; alanine aminotransferase, all grades: 29% vs 8%; grade ≥3: 8% vs 1%) that were reversible in the majority of patients, nausea (all grades: 24% vs 18%; grade ≥3: 1% vs 1%) and decreased appetite (all grades: 22% vs 16%; grade ≥3: 1% vs 1%).[@R25] These adverse events (AEs, Common Terminology Criteria for Adverse Events (CTCAE) V.3.0) were manageable with supportive treatment or dose reduction. The incidence of AEs associated with VEGF inhibition was generally low; bleeding events and hypertension were slightly higher with nintedanib than with placebo. Similarly, the incidence of AEs associated with docetaxel (such as peripheral neuropathy and mucositis) was slightly higher in the nintedanib arm than in the placebo arm. A similar AE profile was observed in the adenocarcinoma population.

In LUME-Lung 2, patients with non-squamous NSCLC were randomised to either nintedanib (200 mg two times a day, n=353) or placebo (n=360) on days 2--21 plus pemetrexed (500 mg/m^2^) on day 1, every 3 weeks. An independent data monitoring committee (DMC) conducted a preplanned futility analysis of investigator-assessed PFS and recommended that the study be halted prematurely. Subsequent analysis demonstrated a significant improvement in centrally reviewed PFS favouring the nintedanib arm over the placebo arm (median PFS 4.4 vs 3.6 months, HR 0.83, 95% CI 0.70 to 0.99, p=0.040).[@R26] A retrospective analysis of the futility calculations indicated that the predefined threshold for futility was only crossed at the time of the futility analysis for investigator-assessed PFS, but not for centrally reviewed PFS at any point during the study, suggesting that the single time point for preplanned futility analysis was inadequate. Nintedanib plus pemetrexed had a manageable safety profile with no new or unexpected findings.

Ramucirumab {#s3b}
-----------

Ramucirumab is an intravenously administered monoclonal antibody that specifically binds to the extracellular domain of VEGFR-2.[@R28] The multicentre, double-blind, randomised phase III REVEL study assessed the efficacy and safety of docetaxel (75 mg/m^2^) plus ramucirumab (10 mg/kg, n=627) or placebo (n=625) every 3 weeks in ECOG PS 0--1 patients with stage IV NSCLC who progressed during or after first-line platinum-based chemotherapy.[@R28] [@R29] The study met its primary end point of OS, with a longer survival reported for ramucirumab plus docetaxel compared with docetaxel plus placebo (10.5 vs 9.1 months, HR 0.86, 95% CI 0.75 to 0.98, p=0.023) ([figure 3](#ESMOOPEN2016000118F3){ref-type="fig"}). Median PFS, a secondary end point, was also higher in the ramucirumab arm versus the placebo arm (4.5 vs 3.0 months, HR 0.76, 95% CI 0.68 to 0.86; p\<0.0001).

![Kaplan-Meier curves for overall survival in the REVEL trial (intent-to-treat population). Reprinted from Garon *et al*.[@R28] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. 665--673, Copyright (2014), with permission from Elsevier.](esmoopen-2016-000118f03){#ESMOOPEN2016000118F3}

REVEL was not powered for subgroup analysis according to histology; however, longer median OS was observed with ramucirumab plus docetaxel than with placebo plus docetaxel in patients with non-squamous NSCLC (n=912; 11.1 months vs 9.7 months; HR 0.83, 95% CI 0.71 to 0.97, p=0.02),[@R28] including patients with adenocarcinoma histology (n=725; 11.2 months vs 9.8 months; HR 0.83, 95% CI 0.69 to 0.99; p value not reported).[@R29] In the squamous population, a numerically longer median OS in the ramucirumab arm did not reach statistical significance (n=328; 9.5 months vs 8.2 months; HR 0.88, 0.69 to 1.13; p=0.32).[@R28] In a univariate exploratory analysis, patients with time since start of prior therapy of \<9 months had a longer OS in the ramucirumab arm versus the placebo arm (HR 0.75, 95% CI 0.64 to 0.88).[@R28]

In REVEL, the most frequently observed AEs (CTCAE V.4.0) in the ramucirumab arm were similar to those observed in the placebo arm and included fatigue (all grades: 55% vs 49%; grade ≥3: 14% vs 10%), decreased appetite (all grades: 29% vs 25%; grade ≥3: 2% vs 1%), diarrhoea (all grades: 32% vs 27%; grade ≥3: 5% vs 3%), nausea (all grades: 27% vs 27%; grade ≥3: 1% vs 1%) and alopecia (all grades: 26% vs 25%; grade ≥3: NA).[@R28] AEs observed more frequently in the ramucirumab arm (≥10% difference between treatment arms) were neutropenia (55% vs 45%) and stomatitis (23% vs 13%). Overall, the toxicities observed with ramucirumab were manageable with dose adjustments or supportive care. AEs associated with VEGF inhibition that were higher in the ramucirumab arm included bleeding (29% vs 15%) with most events related to epistaxis (19% vs 6%), and hypertension (11% vs 5%) with more than half of events at grade ≥3 (6% vs 2%).[@R28] The frequency of grade ≥3 pulmonary haemorrhage was comparable between the treatment arms.

Immune checkpoint inhibitors {#s4}
============================

Results with programmed death receptor-1 (PD-1) inhibitors and PD ligand-1 (PD-L1) inhibitors were encouraging in early clinical trials, leading to several large, randomised phase III trials in previously treated patients with NSCLC.[@R30] PD-1 is expressed on several immune cells, including T cells, B cells and natural killer cells, whereas PD-L1 is expressed on tumour cells, as well as a range of immune effector cells. The PD-1/PD-L1 interaction has a strong immunosuppressive effect in downregulating T-cell function, and blockade of the PD-1/PD-L1 pathway using antagonistic monoclonal antibodies has been shown to increase the number and functionality of tumour-specific T cells ([figure 4](#ESMOOPEN2016000118F4){ref-type="fig"}).[@R31]

![Overview of checkpoint blockade activating antitumour immunity and checkpoint immune inhibitors in development in NSCLC. Reprinted by permission from Macmillan Publishers : Wolchok *et al*.[@R54] MHC, major histocompatibility complex; PD-1, programmed death receptor-1; PD-L1, programmed death receptor ligand-1.](esmoopen-2016-000118f04){#ESMOOPEN2016000118F4}

Nivolumab {#s4a}
---------

Nivolumab is a fully human immunoglobulin (Ig) G4 antibody that disrupts PD-1-mediated signalling and has the potential to restore antitumour immunity.[@R32] Phase III trials for nivolumab versus docetaxel in patients with squamous (CheckMate-017, NCT01642004) and non-squamous (CheckMate-057, NCT01673867) histology after the failure of platinum-based doublet chemotherapy were stopped early following planned interim analyses and a DMC assessment that concluded that both studies met their primary end point, demonstrating superior OS in patients receiving nivolumab when compared to the control arm.[@R32] [@R33] Nivolumab (Opdivo; Bristol-Myers Squibb, New York, USA) has received US and EU approval for the treatment of locally advanced or metastatic NSCLC with progression on or after chemotherapy.[@R34]

In the CheckMate-017 study (n=272), patients with stage IIIB/IV, squamous NSCLC and ECOG 0--1 were randomised to receive nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m^2^ every 3 weeks); patients were required to submit pretreatment (archival or recent) tumour-tissue specimen for retrospective biomarker analyses.[@R33] Treatment with nivolumab improved median OS by 3.2 months from 6.0 months for docetaxel to 9.2 months for nivolumab in patients with squamous NSCLC (HR 0.59, 95% CI 0.44 to 0.79, p\<0.001) ([figure 5](#ESMOOPEN2016000118F5){ref-type="fig"}). PFS also significantly improved (HR 0.62, 95% CI 0.47 to 0.81, p\<0.001). OS and PFS were similar among the subgroups of patients with differing levels of PD-L1 expression.

![Kaplan-Meier curves for overall survival in the CheckMate-017 trial (intent-to-treat population). Reprinted from Brahmer *et al*.[@R33]](esmoopen-2016-000118f05){#ESMOOPEN2016000118F5}

The similarly designed CheckMate-057 study (n=582) also demonstrated a superior OS (median OS 12.2 months vs 9.4 months, HR 0.73, 96% CI 0.59 to 0.89, p=0.002) with nivolumab in patients with non-squamous NSCLC ([figure 6](#ESMOOPEN2016000118F6){ref-type="fig"}).[@R32] There was no significant improvement in PFS (HR 0.92, 95% CI 0.77 to 1.11, p=0.39). In terms of PD-L1 expression, median OS was higher with nivolumab than with docetaxel in patients with ≥1% PD-L1 expression (17.7 months vs 9.0 months, HR 0.58, 95% CI 0.43 to 0.79) but similar in patients with \<1% PD-L1 expression (10.5 months vs 10.1 months, HR 0.87, 95% CI 0.63 to 1.19). Nivolumab appeared to be more effective in patients with a longer time from completion of the most recent regimen to randomisation, with an HR for OS of 0.46 (95% CI 0.27 to 0.79) in patients with more than 6 months from completion of most recent regimen to randomisation versus 0.85 (95% CI 0.67 to 1.08) in patients with \<3 months to randomisation. The most frequently observed any-grade AEs were similar in the two treatment arms (98% vs 99%). Any grade treatment-related AEs were lower with nivolumab than with docetaxel (69% vs 88%) as were grade ≥3 AEs (10% vs 54%). Frequent all-causality AEs (CTCAE V.4.0) with nivolumab included fatigue (all grades: 32% vs 38%; grade 3--4: 3% vs 7%), decreased appetite (all grades: 29% vs 22%; grade 3--4: 2% vs 1%), cough (all grades: 26% vs 23%; grade 3--4: \<1% vs 0), constipation (all grades: 23% vs 17%; grade 3--4: 1% vs 1%), dyspnoea (all grades: 23% vs 24%; grade 3--4: 5% vs 4%), nausea (all grades: 22% vs 30%; grade 3--4: 2% vs 1%) and asthenia (all grades: 21% vs 23%; grade 3--4: 3% vs 4%). Safety profiles were similar between the subgroups of patients with PD-L1 expression of \<1% and ≥1%. Immune-modulating agents were administered to resolve AEs such as rash and pruritus. Safety profiles were comparable in the CheckMate-057 and CheckMate-017 studies.[@R32] [@R33]

![Kaplan-Meier curves for overall survival in the CheckMate-057 trial (intent-to-treat population). Reprinted from Borghaei *et al*.[@R32]](esmoopen-2016-000118f06){#ESMOOPEN2016000118F6}

Pembrolizumab {#s4b}
-------------

Pembrolizumab is a monoclonal IgG4 anti-PD-1 antibody that disrupts the engagement of PD-1 with its ligand.[@R35] The KEYNOTE-001 phase I study (NCT01295827) enrolled 495 patients of whom 101 were treatment-naïve and 394 previously treated for advanced or metastatic NSCLC and with ECOG status 0--1. Overall, 401 (81%) patients had non-squamous histology, 85 (17%) had squamous NSCLC and 9 (2%) had adenosquamous or unknown histology. Treatment with pembrolizumab (2 mg/kg or 10 mg/kg every 3 weeks or 10 mg/kg every 2 weeks) demonstrated antitumour activity (objective response rate (ORR) 19.4%, mean response duration: 12.5 months) and an acceptable side-effect profile in the overall population.[@R35] Biomarker analysis was performed, with results being reported as the percentage of neoplastic cells showing PD-L1 staining (tumour proportion score (TPS)). The biomarker-evaluable population included 73 patients with TPS ≥50% and 131 patients with TPS \<50%. ORR was significantly higher (43.9% vs 14.1%; p\<0.001) for previously treated patients with TPS ≥50% (n=57) than those with TPS \<50% (n=99). Median PFS among patients with a TPS ≥50% was 6.1 months for previously treated patients. At a follow-up analysis with a data cut-off 6 months after the primary data cut-off, among 124 previously treated patients with PD-L1 TPS ≥50%, median PFS was 5.8 months and median OS was 14.0 months (HR not reported).[@R36]

Based on results from the KEYNOTE-001 study, pembrolizumab (Keytruda; Merck & Co, Kenilworth, USA) was granted accelerated approval in the USA for the treatment of patients with metastatic NSCLC whose tumours express PD-L1, as determined by a Food and Drug Administration (FDA)-approved test and who have disease progression on or after platinum-containing chemotherapy.[@R37] The PD-L1 immunohistochemistry (IHC) 22C3 pharmDx test is designed to detect PD-L1 expression, with tumour samples considered to be PD-L1-positive if ≥50% of viable cells exhibit membrane staining. Based on this cut-off, KEYNOTE-001 reported the estimated prevalence of PD-L1-positive patients as 22.7% of the previously treated patient population.[@R35]

In the KEYNOTE-010 phase II/III study (NCT01905657), previously treated PD-L1-positive (TPS ≥1%) patients with advanced NSCLC were randomised in a 1:1:1 ratio to receive either pembrolizumab 2 mg/kg every 3 weeks (n=344), pembrolizumab 10 mg/kg every 3 weeks (n=346) or docetaxel 75 mg/m^2^ every 3 weeks (n=343).[@R38] Primary end points were OS and PFS in the total population and in patients with TPS ≥50%. A total of 724 patients (70.1%) had non-squamous disease, 222 patients (21.5%) had squamous disease and 87 patients (8.4%) had other/unknown histology. In patients with PD-L1 TPS ≥50%, median OS was 14.9 months for the 2 mg/kg group (HR vs docetaxel 0.54, 95% CI 0.38 to 0.77, p=0.0002), 17.3 months for the 10 mg/kg group (HR vs docetaxel 0.50, 95% CI 0.36 to 0.70, p\<0.0001) and 8.2 months for the docetaxel group ([figure 7](#ESMOOPEN2016000118F7){ref-type="fig"}A). In the total population, median OS was 10.4 months (HR vs docetaxel 0.71, 95% CI 0.58 to 0.88, p=0.0008) for patients treated with pembrolizumab 2 mg/kg, 12.7 months (HR vs docetaxel 0.61, 95% CI 0.49 to 0.75, p\<0.0001) for the pembrolizumab 10 mg/kg arm and 8.5 months for the docetaxel arm ([figure 7](#ESMOOPEN2016000118F7){ref-type="fig"}B). Patients with adenocarcinoma (n=708) had greater OS benefit with pembrolizumab compared with docetaxel treatment (HR 0.63, 95% CI 0.50 to 0.79). PFS improvement was not statistically significant for either pembrolizumab arm versus docetaxel. Treatment-related AEs (CTCAE V.4.0) at any grade and at grade ≥3 were more frequent with docetaxel with either dose of pembrolizumab (all grades: pembrolizumab 2 mg/kg 63%, pembrolizumab 10 mg/kg 66%, docetaxel 81%; grade ≥3: pembrolizumab 2 mg/kg 13%, pembrolizumab 10 mg/kg 16%, docetaxel 35%). Treatment-related AEs that were frequent with pembrolizumab included decreased appetite (all grades: 14% vs 10% vs 16%; grade ≥3: 1% vs \<1% vs 1%), fatigue (all grades: 14% vs 14% vs 25%; grade ≥3: 1% vs 2% vs 4%), nausea (all grades: 11% vs 9% vs 15%; grade ≥3: \<1% vs 1% vs \<1%) and rash (all grades: 9% vs 13% vs 5%; grade ≥3: \<1% vs \<1% vs 0). Immune-mediated AEs occurred at manageable rates, although three (\<1%) of the 682 pembrolizumab-treated patients died of pneumonitis. Safety profiles were comparable in the KEYNOTE-001 and KEYNOTE-010 studies.[@R35] [@R38]

![Kaplan-Meier curves for overall survival in patients with PD-L1 tumour proportion score of ≥50% (A) and all patients from KEYNOTE-010 (B). Adapted from Herbst *et al*.[@R38] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. 1540--1550, Copyright (2015), with permission from Elsevier.](esmoopen-2016-000118f07){#ESMOOPEN2016000118F7}

Other checkpoint inhibitors {#s4c}
---------------------------

In this rapidly advancing area of clinical research other PD-L1 checkpoint inhibitors are being intensively investigated including atezolizumab (MPDL3280A, Roche), durvalumab (MEDI4736, AstraZeneca) and avelumab (MSB0010718C, Merck KGaA/Pfizer). Of these investigational agents atezolizumab has recently received Breakthrough Therapy Designation from the FDA, based on results in PD-L1-positive NSCLC.[@R39] Results from an open-label, phase 2 randomised controlled trial, in patients with advanced NSCLC who progressed on postplatinum chemotherapy showed that atezolizumab significantly improved survival compared with docetaxel (12.6 months, 95% CI 9.7 to 16.4 vs 9.7 months 95% CI 8.6 to 12.0; HR=0.73, 95% CI 0.53 to 0.99; p=0.04). Increasing improvement in OS was also noted in patients with higher levels of PD-L1 expression treated with atezolizumab compared with docetaxel.[@R40] Although the clinical programme is not as advanced as atezolizumab, treatment with durvalumab in combination with the cytotoxic T-lymphocyte-associated protein 4 inhibitor tremelimumab in patients with locally advanced or metastatic NSCLC showed evidence of clinical activity in patients with PD-L1-positive tumours and in those with PD-L1-negative tumours. The response in PD-L1 negative tumours represents a potential therapeutic option for a group of patients who have not benefited as much from the use of other checkpoint inhibitors in trials undertaken to date.[@R41] Other studies are being undertaken as summarised in [table 2](#ESMOOPEN2016000118TB2){ref-type="table"} and in general checkpoint inhibitors have also shown encouraging trends across other solid tumour types, in phase I development.[@R42]

###### 

Overview of phase III trials of antiprogrammed death receptor-1 (PD-1)/programmed death receptor ligand-1 (PD-L1) inhibitors completed or ongoing in previously treated patients with advanced NSCLC

  Agent                        Target                                                                                                       Trial name, identifier          Design
  ---------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nivolumab                    PD-1                                                                                                         CheckMate-057, NCT01673867      Nivolumab in previously treated patients with NSCLC vs docetaxel alone in patients with non-squamous histology
  CheckMate-017, NCT01642004   Nivolumab in previously treated patients with NSCLC vs docetaxel alone in patients with squamous histology                                   
  Pembrolizumab                PD-1                                                                                                         KEYNOTE-010, NCT01905657        Pembrolizumab vs docetaxel in patients with NSCLC who have experienced disease progression after platinum-containing therapy
  Atezolizumab (MPDL3280A)     PD-L1                                                                                                        OAK, NCT02008227                MPDL3280A vs docetaxel in patients with locally advanced or metastatic NSCLC who have failed platinum therapy
  Durvalumab (MEDI4736)        PD-L1                                                                                                        ARCTIC, NCT02352948             MEDI4736, given as monotherapy or in combination with tremelimumab, determined by PD-L1 expression vs standard of care in patients with locally advanced or metastatic NSCLC
  Avelumab (MSB0010718C)       PD-L1                                                                                                        JAVELIN Lung 200, NCT02395172   MSB0010718C vs docetaxel in patients with PD-L1-positive, advanced NSCLC after failure of a platinum-containing doublet

NSCLC, non-small cell lung cancer; PD-1, programmed death receptor-1; PD-L1, programmed death receptor ligand-1.

Predictive and prognostic factors {#s5}
=================================

Approaches to identify biomarkers/clinical markers include genotyping and simpler assessment of tissue samples, such as pathological and molecular tumour features, grade and pathology of the tumour, as well as plasma/serum markers. Characterising tumours according to histological subtype and genetic composition has resulted in significant progress in the identification of response to certain drugs, for example, the epidermal growth factor receptor (EGFR)-activating mutations.[@R47]

Antiangiogenic agents {#s5a}
---------------------

Despite progress in the identification of predictive biomarkers in patients with differing tumour mutational status, none have been identified for those who receive antiangiogenic agents.[@R48] [@R49] A major challenge in identifying potential biomarkers to antiangiogenic therapy is the complex nature of the angiogenic signalling process, which is characterised by multiple overlapping pathways.[@R50] The activation of compensatory bypass angiogenic pathways after initial treatment response is a significant roadblock as it results in the development of resistance.[@R50] Consequently, there remains an urgent need for biomarkers to angiogenesis inhibitors in the treatment of cancer, including NSCLC.[@R51]

Analyses of the LUME-Lung 1 study have been conducted to identify a prognostic and/or predictive factor for the OS improvement observed in adenocarcinoma patients who received nintedanib plus docetaxel after first-line therapy.[@R52] The analysis also used data from patients in the LUME-Lung 2 trial. These analyses suggest that: (1) time since the start of first-line therapy was a prognostic and predictive clinical biomarker for the treatment effect of nintedanib, combined with either docetaxel or pemetrexed, for patients with advanced non-squamous NSCLC, progressing after platinum-based chemotherapy; and (2) a treatment benefit was evident in those non-squamous patients with a particularly poor prognosis who progressed during or shortly after first-line treatment. Results from the REVEL study also confirm time since the start of first-line therapy as a potential clinical marker for ramucirumab.[@R28]

PD-1/PD-L1 inhibition {#s5b}
---------------------

PD-L1 is upregulated in many cancer types and contributes to malignancy by inhibiting T-cell activation, limiting tumour cell killing by the immune system; PD-L1 expression assessed by IHC is being investigated as a marker for many anti-PD-1/PD-L1 agents.[@R22] [@R23] PD-L1 positivity may indicate that an immune-active tumour may be sensitive to anti-PD-1 or PD-L1 therapy because of a correlation with PD-L1 expression and poor prognosis in cancers, including lung adenocarcinoma.[@R22] However, the predictive and/or prognostic uses of PD-L1 expression remain unclear. Several studies have shown improved responses to anti-PD-1 or anti-PD-L1 therapy in 'PD-L1-positive' cases; however, most studies also report significant response rates (3--30%) in PD-L1-negative tumours. There is variable definition of PD-L1 positivity in tumours, ranging from ≥1% to ≥50% of cells assessed showing PD-L1 expression. PD-L1 has dynamic expression, which could, together with heterogeneous expression, confound the determination of a positive or negative assay result. Despite the different approaches to PD-L1 assessment for each of the drugs in this class, an association between expression and response has been reasonably consistent. The presence of response in patients deemed to be PD-L1-negative has called into question the validity of this biomarker. Undoubtedly, the PD-L1 biomarker does not show the predictive performance of EGFR mutation or ALK fusion for targeted therapy with TKIs. However, the biology of the immune system, the action of the therapy and the nature of the IHC test all mean that lesser predictive power is inevitable.

To date, concordance between the different IHC antibodies used in the trials has not been reported. The assays available vary in their ability to detect PD-L1, and although some assays consider tumour cell expression, others also score immune-cell PD-L1 expression.[@R22] Low staining thresholds, such as 1% or 5%, reflect the fact that PD-L1 expression is heterogeneous; however, they carry a greater risk that scoring will be inconsistent and an inaccurate representation of a patient\'s tumour burden.[@R23] Small sample sizes in these studies may also play a role.

The variability in PD-L1 testing used and validated in trials poses serious challenges for pathologists in delivering this biomarker test, assuming it will be requested. An international effort for a standardised approach could enable the use of PD-L1 expression as a reliable biomarker for anti-PD-1/PD-L1 therapy.[@R23]

Plasma and circulating tumour cells have also been proposed as alternative forms of non-invasive, blood-based biomarker analysis.[@R22] Plasma PD-L1 protein could provide a method for monitoring PD-1/PD-L1 interaction in NSCLC.

Future directions {#s6}
=================

Defining 'clinically meaningful' benefit is complex and a balance is needed between 'objective' end points (which have value in benchmarking) versus 'subjective' end points, including patient-oriented factors such as symptom relief, quality of life and toxicity reduction. Median OS remains an important outcome for benchmarking of clinical practice, but other measures should be considered, including survival HR, 1-year and 2-year survival rates, and patient-related factors.

It is important to continue the search for clinical and molecular prognostic and predictive factors. Patient selection through the use of biomarkers is important in choosing the correct treatment option. A shorter time since start of first-line therapy is a potential clinical marker for the antiangiogenic agents, considering the lower OS benefit from immunotherapy in patients with shorter time since completion of their most recent chemotherapy regimen. Collection of tumour and blood samples is essential in future studies to help identify biomarkers in order to select patients who will benefit the most. In addition, a standardised approach to measuring PD-L1 expression is needed to be a consistent biomarker for anti-PD-1/PD-L1 therapy.

Conclusions {#s7}
===========

In the past few years, new treatment options have become available for patients with NSCLC whose disease has progressed after or during first-line chemotherapy. This has come after a decade of only few advances in this setting, and holds promise for the future evolution of the management of NSCLC.
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